Results 51 to 60 of about 236,716 (237)

Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor

open access: yesHaematologica, 2008
Imatinib mesylate is a tyrosine kinase inhibitor used as first line treatment in chronic myeloid leukemia and gastrointestinal stromal tumorpatients. Although several in vitro and animal studies demonstrated that imatinib affects immune response, few ...
Rita Santachiara   +13 more
doaj   +1 more source

Blocking the APRIL circuit enhances acute myeloid leukemia cell chemosensitivity

open access: yesHaematologica, 2008
Resistance to chemotherapy-induced cell death represents a major obstacle in the treatment of acute myeloid leukemia. APRIL (A Proliferation Inducing Ligand) is a member of the tumor necrosis factor superfamily that plays a key role in normal B-cell ...
Désirée Bonci   +8 more
doaj   +1 more source

Immunophenotypes of Acute Myeloid Leukemia From Flow Cytometry Data Using Templates [PDF]

open access: yesarXiv, 2014
Motivation: We investigate whether a template-based classification pipeline could be used to identify immunophenotypes in (and thereby classify) a heterogeneous disease with many subtypes. The disease we consider here is Acute Myeloid Leukemia, which is heterogeneous at the morphologic, cytogenetic and molecular levels, with several known subtypes. The
arxiv  

Optimized Treatment Schedules for Chronic Myeloid Leukemia [PDF]

open access: yes, 2016
Over the past decade, several targeted therapies (e.g. imatinib, dasatinib, nilotinib) have been developed to treat Chronic Myeloid Leukemia (CML). Despite an initial response to therapy, drug resistance remains a problem for some CML patients. Recent studies have shown that resistance mutations that preexist treatment can be detected in a substan ...
arxiv   +1 more source

Chronic myeloid leukemia in Asia

open access: yesInternational Journal of Hematology, 2008
Chronic myeloid leukemia (CML) in Asia has an incidence rather lower than in Western countries yet tends to afflict a younger population. As in the West, imatinib mesylate (IM, Glivec) has supplanted busulphan, hydroxyurea and interferon-alpha as first-line treatment.
Jootar, S   +9 more
openaire   +4 more sources

Impact of IDH Mutations on DNA Methylation of Acute Myeloid Leukemia Related Genes: A Review Article

open access: yesمجلة كلية الطب
Background: Acute myeloid leukemia is one of the deadliest hematologic malignancies that is marked by genetic alterations, abnormal cellular functions, and proliferation. Mutations in isocitrate dehydrogenase genes, particularly isocitrate dehydrogenase
Duha M. Bayram   +2 more
doaj   +1 more source

De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways

open access: yesHaematologica, 2019
Despite the advent of tyrosine kinase inhibitors, a proportion of chronic myeloid leukemia patients in chronic phase fail to respond to imatinib or to second-generation inhibitors and progress to blast crisis. Until now, improvements in the understanding
Vera Magistroni   +27 more
doaj   +1 more source

IRE1 alpha may be causing abnormal loss of p53 at post transcriptional level in chronic myeloid leukemia [PDF]

open access: yesarXiv, 2017
Current treatment strategy for chronic myeloid leukemia (CML) mainly includes inhibition of tyrosine kinase activity, which has dramatically improved the prognosis of the disease but without cure. In addition some patients may become drug resistant. Thus there is still the need for other therapies to avoid resistance and if possible to cure the disease.
arxiv  

Improvement of platelet dysfunction in chronic myelogenous leukemia following treatment with imatinib: a case report

open access: yesJournal of Medical Case Reports, 2011
Introduction In patients with chronic myeloid leukemia, tyrosine kinase inhibitors suppress the BCR-ABL+ clone and often induce complete molecular remissions.
Scheid Christoph   +5 more
doaj   +1 more source

Proteomics Analysis of FLT3-ITD Mutation in Acute Myeloid Leukemia Using Deep Learning Neural Network [PDF]

open access: yesarXiv, 2017
Deep Learning can significantly benefit cancer proteomics and genomics. In this study, we attempt to determine a set of critical proteins that are associated with the FLT3-ITD mutation in newly-diagnosed acute myeloid leukemia patients. A Deep Learning network consisting of autoencoders forming a hierarchical model from which high-level features are ...
arxiv  

Home - About - Disclaimer - Privacy